NASDAQ:CLLSCellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLLS shares have increased by 49.8% and is now trading at $17.12.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.59) by $1.06. The biotechnology company earned $51.91 million during the quarter, compared to the consensus estimate of $21.07 million. Cellectis had a negative return on equity of 18.00% and a negative net margin of 89.50%.
View Cellectis' earnings history.

7 analysts have issued 1 year price objectives for Cellectis' shares. Their forecasts range from $11.00 to $73.00. On average, they anticipate Cellectis' stock price to reach $32.17 in the next twelve months. This suggests a possible upside of 87.9% from the stock's current price.
View analysts' price targets for Cellectis.

News articles about CLLS stock have trended somewhat negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellectis earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Cellectis.

Cellectis saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 359,300 shares, an increase of 39.9% from the June 15th total of 256,900 shares. Based on an average daily trading volume, of 216,100 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the shares of the stock are sold short.
View Cellectis' Short Interest.

Some companies that are related to Cellectis include Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Regenxbio (RGNX) and Beam Therapeutics (BEAM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Intellia Therapeutics (NTLA), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (2.53%), Sumitomo Mitsui Trust Holdings Inc. (1.73%), Prosight Management LP (0.65%), Hudson Bay Capital Management LP (0.38%), New York State Common Retirement Fund (0.25%) and Vident Investment Advisory LLC (0.20%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Sumitomo Mitsui Trust Holdings Inc., Bank of America Corp DE, Hudson Bay Capital Management LP, UBS Group AG, WS Management Lllp, Vident Investment Advisory LLC, and Vident Investment Advisory LLC.

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Ikarian Capital LLC, Marshall Wace LLP, Marshall Wace North America L.P., RMB Capital Management LLC, Exchange Traded Concepts LLC, Princeton Capital Management LLC, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $17.12.

Cellectis has a market capitalization of $727.02 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]